{"id":461,"date":"2026-08-12T13:58:25","date_gmt":"2026-08-12T11:58:25","guid":{"rendered":"https:\/\/reborn-peptides.com\/knowledge\/retatrutide-glossary\/"},"modified":"2026-09-07T11:52:29","modified_gmt":"2026-09-07T09:52:29","slug":"retatrutide-glossary","status":"publish","type":"page","link":"https:\/\/reborn-peptides.com\/en\/knowledge\/retatrutide-glossary\/","title":{"rendered":"LY3437943 (Retatrutide): Research Glossary"},"content":{"rendered":"

Research use only.<\/strong> This glossary describes retatrutide (LY3437943) as a laboratory research material. It does not provide instructions for preparation, administration or use.<\/p>\n

What is reta peptide?<\/h2>\n

\u201cReta peptide\u201d is the short form the research community uses for retatrutide \u2014 both terms describe the same material, and \u201cReta\u201d is an abbreviation rather than a separate compound name. What is reta peptide<\/strong> therefore has the same answer as what is retatrutide<\/em>. Retatrutide, also identified by the development code LY3437943<\/strong>, is a synthetic, lipidated peptide of approximately 39 amino acids. In experimental systems, it acts as an agonist at three class B1 G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR<\/strong>), glucagon-like peptide-1 receptor (GLP-1R<\/strong>) and glucagon receptor (GCGR<\/strong>). For that reason, the research literature describes it as a triple receptor agonist<\/strong>.<\/p>\n

A 2024 cryogenic electron microscopy study reported how the same peptide engages all three receptors at the structural level (Li et al. 2024, PMID 39019866<\/a>). This retatrutide glossary brings together the terminology, substance identity, receptor pharmacology and study-model context most relevant to laboratory research.<\/p>\n

Name glossary: Reta peptide, Triple G and GLP-3<\/h2>\n

Reta<\/h3>\n

Reta<\/strong> is an informal abbreviation used for retatrutide. It is not a separate compound name, and it does not designate a substance class: wherever the short form appears in a research context, the material meant is retatrutide (LY3437943). Documentation, labelling and batch records use the full name.<\/p>\n

Reta peptide<\/h3>\n

Reta peptide<\/strong> is widespread informal shorthand for retatrutide (LY3437943). Technical documentation uses the full substance name or the development code. For the terminology question is reta a peptide<\/em>, the relevant identity is this synthetic, lipidated peptide.<\/p>\n

Triple G<\/h3>\n

Triple G<\/strong> refers to the peptide’s experimentally described agonism at GIPR, GLP-1R and GCGR. The term is shorthand for a three-receptor pharmacology profile; it is not a distinct substance.<\/p>\n

Tripleg<\/h3>\n

Tripleg<\/strong> is a spelling variant of Triple G found in informal searches. It likewise refers to retatrutide and its GIPR\/GLP-1R\/GCGR activity.<\/p>\n

GLP-3<\/h3>\n

GLP-3<\/strong> is an informal but scientifically misleading label sometimes used for retatrutide. No \u201cGLP-3 receptor\u201d is involved. The reported targets are GIPR, GLP-1R and GCGR (Coskun et al. 2022, PMID 35985340<\/a>; Li et al. 2024, PMID 39019866<\/a>).<\/p>\n

These aliases are included for search and terminology clarity. They establish the retatrutide meaning across informal and technical terminology. Reborn Peptides uses the scientifically established name retatrutide<\/strong> and the documented development code LY3437943<\/strong> when identifying the research material.<\/p>\n

Substance identity: the development code LY3437943<\/h2>\n

LY3437943<\/strong> is the development code under which this material is registered in clinical trial databases and cited in the primary literature; documentation, labelling and batch records use it alongside the INN retatrutide. Retatrutide is a lipidated peptide<\/strong> of approximately 39 amino acids. Its backbone includes deliberately incorporated non-natural residues, including aminoisobutyric acid (Aib) and \u03b1-methyl-leucine. A C20 fatty diacid is attached to a lysine side chain through a linker containing \u03b3-glutamate and AEEA units. The lipid moiety supports serum-albumin binding (Coskun et al. 2022, PMID 35985340<\/a>, DOI 10.1016\/j.cmet.2022.07.013<\/code>; preclinical research).<\/p>\n

Documented identifier:<\/strong> CAS 2381089-83-2 is reported consistently across multiple independent registry and database sources cited in the German evidence workflow.<\/p>\n

Molecular formula and molecular weight must be checked against the documentation for the relevant released batch; this glossary therefore does not present either value as established. Until that check against the released batch documentation is complete, this glossary describes the sequence qualitatively as a lipidated peptide with the structural features supported by the cited literature.<\/p>\n

Substance class: what \u201ctriple-receptor agonist\u201d means<\/h2>\n

GIPR, GLP-1R and GCGR belong to the class B1 family of G-protein-coupled receptors and differ in how they recognise ligands. A dual agonist addresses two receptor types; retatrutide has experimentally characterised agonist activity at all three.<\/p>\n

The glucagon-receptor component<\/strong> distinguishes this pharmacological design from dual GLP-1\/GIP receptor agonism (Coskun et al. 2022, PMID 35985340<\/a>). The retatrutide mechanism of action<\/strong> reported in these sources is therefore a three-receptor profile rather than a single-target one, which makes the molecule relevant to controlled laboratory comparisons involving three receptor systems. How receptor agonists sit alongside other groups of research material is set out in the overview of compound classes<\/a>; the neighbouring dual-agonist materials are listed under tirzepatide analogues<\/a>.<\/p>\n

This classification describes receptor activity observed in defined research models. It does not establish suitability for human or veterinary use and should not be read as a claim of therapeutic benefit.<\/p>\n

Research areas and model types<\/h2>\n

In vitro receptor pharmacology<\/h3>\n

In vitro experiments reported balanced activity at GCGR and GLP-1R, alongside relatively greater activity at GIPR (Coskun et al. 2022, PMID 35985340<\/a>; preclinical research). The finding is model-specific and should be interpreted within the experimental conditions of the cited study.<\/p>\n

Structural biology: cryo-EM<\/h3>\n

Cryo-EM structures show retatrutide adopting a continuous helix. Its N-terminal segment enters the transmembrane core, while its C-terminal region interacts with the extracellular domain. Conserved contacts are retained while receptor-specific differences, including differences at extracellular loop 1 (ECL1), are accommodated (Li et al. 2024, PMID 39019866<\/a>, DOI 10.1038\/s41421-024-00700-0<\/code>; in vitro).<\/p>\n

For multi-target peptide research, these structures provide a concrete reference for examining which contacts contribute to receptor selectivity and which regions tolerate variation.<\/p>\n

What evidence types exist?<\/h3>\n

The published literature cited for this substance spans four broad evidence levels: in vitro structural biology, preclinical receptor and rodent models, phase 1 pharmacokinetic research, and randomised clinical studies from phases 1b to 2a. The presence of human studies does not change the status or intended purpose of research material sold for laboratory use only. What each of these evidence levels can and cannot support is described in the guide to study models<\/a>.<\/p>\n